BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, Liu J, Zhang X, Zhang X, Jin Y, Wang Y, Zhang S, Zhu L, Jacob A, Jia R, You X, Li X, Li C, Zhou Y, Yang Y, Ye H, Liu Y, Su Y, Shen N, Alexander J, Guo J, Ambrus J, Lin X, Yu D, Sun X, Li Z. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2020;79:141-9. [PMID: 31537547 DOI: 10.1136/annrheumdis-2019-215396] [Cited by in Crossref: 66] [Cited by in F6Publishing: 98] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Soelistyoningsih D, Susianti H, Kalim H, Handono K. The phenotype of CD3-CD56bright and CD3-CD56dim natural killer cells in systemic lupus erythematosus patients and its relation to disease activity. Reumatologia 2022;60:258-65. [PMID: 36186836 DOI: 10.5114/reum.2022.119042] [Reference Citation Analysis]
2 Doglio M, Alexander T, Del Papa N, Snowden JA, Greco R; Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies. J Allergy Clin Immunol 2022:S0091-6749(22)01056-9. [PMID: 36137815 DOI: 10.1016/j.jaci.2022.08.003] [Reference Citation Analysis]
3 Wang Q, Wang Y, Qiao W, Xu B, Liu Y, Zhang X, Li W, Zhao J, Liu M, Zhang Y, Chen D, Huang C, Jin R. The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism. Front Immunol 2022;13:995223. [DOI: 10.3389/fimmu.2022.995223] [Reference Citation Analysis]
4 Zheng X, Su R, Hu F, Liu Y, Li X, Gao C, Wang C. Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV/CMV viremia. Autoimmun Rev 2022;21:103186. [PMID: 36084894 DOI: 10.1016/j.autrev.2022.103186] [Reference Citation Analysis]
5 Gao X, He J, Sun X, Li F. Dynamically modeling the effective range of IL-2 dosage in the treatment of systemic lupus erythematosus. iScience 2022;25:104911. [DOI: 10.1016/j.isci.2022.104911] [Reference Citation Analysis]
6 Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, Leroux D, Vazquez T, Riemekasten G, Smolen JS, Tsokos G, Klatzmann D. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis 2022:annrheumdis-2022-222501. [PMID: 35973803 DOI: 10.1136/ard-2022-222501] [Reference Citation Analysis]
7 Zhao Y, Qi Y, Liu X, Cui Y, Zhao Z, Ciccacci C. Efficiency of Disease and Disease Activity Diagnosis Models of Systemic Lupus Erythematosus Based on Protein Array Analysis. Journal of Immunology Research 2022;2022:1-14. [DOI: 10.1155/2022/1830431] [Reference Citation Analysis]
8 Sharkey P, Thomas R. Immune tolerance therapies for autoimmune diseases: Shifting the goalpost to cure. Current Opinion in Pharmacology 2022;65:102242. [DOI: 10.1016/j.coph.2022.102242] [Reference Citation Analysis]
9 Wu R, Mu Y, Zhao X, Zhao J, Gao C, Li X, Wang C. Short-term and low-dose IL-2 therapy increases the reduced Treg cells in patients with microscopic polyangiitis. Autoimmun Rev 2022;:103156. [PMID: 35896124 DOI: 10.1016/j.autrev.2022.103156] [Reference Citation Analysis]
10 Rojas M, Heuer LS, Zhang W, Chen Y, Ridgway WM. The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes. Front Immunol 2022;13:918837. [DOI: 10.3389/fimmu.2022.918837] [Reference Citation Analysis]
11 Maz MP, Martens JWS, Hannoudi A, Reddy AL, Hile GA, Kahlenberg JM. Recent advances in cutaneous lupus. J Autoimmun 2022;:102865. [PMID: 35858957 DOI: 10.1016/j.jaut.2022.102865] [Reference Citation Analysis]
12 Liu Y, Yu X, Zhang W, Zhang X, Wang M, Ji F. Mechanistic insight into premature atherosclerosis and cardiovascular complications in systemic lupus erythematosus. J Autoimmun 2022;:102863. [PMID: 35853760 DOI: 10.1016/j.jaut.2022.102863] [Reference Citation Analysis]
13 Chen P, Zhou Y, Wu L, Chen S, Han F. Efficacy and Safety of Biologic Agents for Lupus Nephritis: A Systematic Review and Meta-analysis. J Clin Rheumatol 2022. [PMID: 35699520 DOI: 10.1097/RHU.0000000000001877] [Reference Citation Analysis]
14 Tsuruta H, Mizuno-Kamiya M, Takahashi M, Ando M, Ikeno K, Ueno K, Takayama E, Kawaki H, Nakamura G, Nikaido T, Fujita H, Kondoh N. Enhanced production of IL-2 from anti-CD3 antibody-stimulated mouse spleen cells by artepillin C, a major component of Brazilian green propolis. J Oral Biosci 2022:S1349-0079(22)00092-5. [PMID: 35667586 DOI: 10.1016/j.job.2022.05.007] [Reference Citation Analysis]
15 Zhou P. Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity. Cytokine & Growth Factor Reviews 2022. [DOI: 10.1016/j.cytogfr.2022.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yuan Y, Kolios AGA, Liu Y, Zhang B, Li H, Tsokos GC, Zhang X. Therapeutic potential of interleukin-2 in autoimmune diseases. Trends Mol Med 2022:S1471-4914(22)00106-X. [PMID: 35624009 DOI: 10.1016/j.molmed.2022.04.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Chiapparoli I, Galluzzo C, Salvarani C, Pipitone N. A glance into the future of myositis therapy. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2211002. [DOI: 10.1177/1759720x221100299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Xie JF, Wang J, Bai HH, He JJ, Jia RH, Wang X, Zhang WQ, Zhao XC, Zhang XC, Liu GY, Li XF. A Decreased Absolute Number of Treg Cells in Patients with Active Rheumatoid Arthritis is Associated with Elevated Serum Osteopontin Levels with Disease Progression. Adv Ther 2022. [PMID: 35604524 DOI: 10.1007/s12325-022-02171-9] [Reference Citation Analysis]
19 Aringer M, Finzel S, Voll RE. [Immunopathogenesis of systemic lupus erythematosus]. Z Rheumatol 2022. [PMID: 35551439 DOI: 10.1007/s00393-022-01214-4] [Reference Citation Analysis]
20 Trzupek D, Lee M, Hamey F, Wicker LS, Todd JA, Ferreira RC. Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus. Wellcome Open Res 2021;6:149. [DOI: 10.12688/wellcomeopenres.16883.2] [Reference Citation Analysis]
21 Tenbrock K, Rauen T. T cell dysregulation in SLE. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.109031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Nikolopoulos D, Fotis L, Gioti O, Fanouriakis A. Tailored treatment strategies and future directions in systemic lupus erythematosus. Rheumatol Int 2022. [PMID: 35449237 DOI: 10.1007/s00296-022-05133-0] [Reference Citation Analysis]
23 Zhang JQ, Zhang SX, Wang J, Qiao J, Qiu MT, Wu XY, Chen JW, Gao C, Li XF. Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection. Curr Med Res Opin 2022;:1-23. [PMID: 35414310 DOI: 10.1080/03007995.2022.2065145] [Reference Citation Analysis]
24 Bolouri N, Akhtari M, Farhadi E, Mansouri R, Faezi ST, Jamshidi A, Mahmoudi M. Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus. Inflamm Res 2022. [PMID: 35298669 DOI: 10.1007/s00011-022-01554-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
25 Zhufeng Y, Xu J, Miao M, Wang Y, Li Y, Huang B, Guo Y, Tian J, Sun X, Li J, Lu D, Li Z, Li Y, He J. Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study. Front Cell Infect Microbiol 2022;12:757099. [DOI: 10.3389/fcimb.2022.757099] [Reference Citation Analysis]
26 Mak A. T Cells, Interleukin-2 and Systemic Lupus Erythematosus—From Pathophysiology to Therapy. Cells 2022;11:980. [DOI: 10.3390/cells11060980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lee J, Kim D, Min B. Tissue Resident Foxp3+ Regulatory T Cells: Sentinels and Saboteurs in Health and Disease. Front Immunol 2022;13:865593. [DOI: 10.3389/fimmu.2022.865593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Zhang X, Miao M, Zhang R, Liu X, Zhao X, Shao M, Liu T, Jin Y, Chen J, Liu H, Zhang X, Li Y, Zhou Y, Yang Y, Li R, Yao H, Liu Y, Li C, Li Y, Ren L, Su Y, Sun X, He J, Li Z. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-00887-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
29 Caza T, Wijewardena C, Al-rabadi L, Perl A. Cell Type-Specific Mechanistic Target of Rapamycin-Dependent Distortion of Autophagy Pathways in Lupus Nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Fanton C, Furie R, Chindalore V, Levin R, Diab I, Dixit N, Haglund C, Gibbons J, Hanan N, Dickerson D, Zalevsky J, Kotzin BL. Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. Journal of Translational Autoimmunity 2022. [DOI: 10.1016/j.jtauto.2022.100152] [Reference Citation Analysis]
31 Lu Z, Tian Y, Bai Z, Liu J, Zhang Y, Qi J, Jin M, Zhu J, Li X. Increased oxidative stress contributes to impaired peripheral CD56dimCD57+ NK cells from patients with systemic lupus erythematosus. Arthritis Res Ther 2022;24:48. [PMID: 35172900 DOI: 10.1186/s13075-022-02731-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Soybilgic A. Biologic Agents and Other Emerging Therapies for Childhood SLE. Pediatr Ann 2022;51. [DOI: 10.3928/19382359-20220118-01] [Reference Citation Analysis]
33 Han J, Ren G, Xu Z, Qi W, Shang Y, Wen S, Luo Y. Exploring the relationship between systemic lupus erythematosus and osteoporosis based on bioinformatics. Lupus 2022;:9612033211073909. [PMID: 35067074 DOI: 10.1177/09612033211073909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Mucke J, Schneider M. Innovationen in der Arzneimitteltherapie des systemischen Lupus erythematodes. Internist. [DOI: 10.1007/s00108-021-01250-3] [Reference Citation Analysis]
35 Rajendeeran A, Tenbrock K. Regulatory T cell function in autoimmune disease. J Transl Autoimmun 2021;4:100130. [PMID: 35005594 DOI: 10.1016/j.jtauto.2021.100130] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Tsang-A-Sjoe MWP, Bultink IEM. New developments in systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:vi21-8. [PMID: 34951924 DOI: 10.1093/rheumatology/keab498] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Dang VD, Stefanski AL, Lino AC, Dörner T. B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives. J Invest Dermatol 2021:S0022-202X(21)02470-2. [PMID: 34955289 DOI: 10.1016/j.jid.2021.05.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Kolios AGA, Tsokos GC, Klatzmann D. Interleukin-2 and regulatory T cells in rheumatic diseases. Nat Rev Rheumatol 2021;17:749-66. [PMID: 34728817 DOI: 10.1038/s41584-021-00707-x] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
39 Idborg H, Oke V. Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy. Int J Mol Sci 2021;22:11327. [PMID: 34768756 DOI: 10.3390/ijms222111327] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
40 Connelly K, Vettivel J, Golder V, Kandane-Rathnayake R, Morand EF. Measurement of specific organ domains in lupus randomised controlled trials: a scoping review. Rheumatology (Oxford) 2021:keab777. [PMID: 34664636 DOI: 10.1093/rheumatology/keab777] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Zhou P, Chen J, He J, Zheng T, Yunis J, Makota V, Alexandre YO, Gong F, Zhang X, Xie W, Li Y, Shao M, Zhu Y, Sinclair JE, Miao M, Chen Y, Short KR, Mueller SN, Sun X, Yu D, Li Z. Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus. PLoS Pathog 2021;17:e1009858. [PMID: 34618873 DOI: 10.1371/journal.ppat.1009858] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
42 Zhang X, Feng R, Shao M, Wang Y, Sun X, He J. Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis. Rheumatol Ther 2021;8:1905-14. [PMID: 34618348 DOI: 10.1007/s40744-021-00381-1] [Reference Citation Analysis]
43 Zhang B, Sun J, Wang Y, Ji D, Yuan Y, Li S, Sun Y, Hou Y, Li P, Zhao L, Yu F, Ma W, Cheng B, Wu L, Hu J, Wang M, Song W, Li X, Li H, Fei Y, Chen H, Zhang L, Tsokos GC, Zhou D, Zhang X. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat Biomed Eng 2021;5:1288-305. [PMID: 34580438 DOI: 10.1038/s41551-021-00797-8] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
44 Nakayamada S, Tanaka Y. Clinical relevance of T follicular helper cells in systemic lupus erythematosus. Expert Rev Clin Immunol 2021;17:1143-50. [PMID: 34469695 DOI: 10.1080/1744666X.2021.1976146] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
45 Puri P, Jiang SH, Yang Y, Mackay F, Yu D. Understand SLE heterogeneity in the era of omics, big data, and artificial intelligence. Rheumatology & Autoimmunity 2021;1:40-51. [DOI: 10.1002/rai2.12010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Nash A, Aghlara-Fotovat S, Hernandez A, Scull C, Veiseh O. Clinical translation of immunomodulatory therapeutics. Adv Drug Deliv Rev 2021;176:113896. [PMID: 34324885 DOI: 10.1016/j.addr.2021.113896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Beurier P, Ricard L, Eshagh D, Malard F, Siblany L, Fain O, Mohty M, Gaugler B, Mekinian A. TFH cells in systemic sclerosis. J Transl Med 2021;19:375. [PMID: 34461933 DOI: 10.1186/s12967-021-03049-0] [Reference Citation Analysis]
48 Yang M, Yi P, Jiang J, Zhao M, Wu H, Lu Q. Dysregulated translational factors and epigenetic regulations orchestrate in B cells contributing to autoimmune diseases. Int Rev Immunol 2021;:1-25. [PMID: 34445929 DOI: 10.1080/08830185.2021.1964498] [Reference Citation Analysis]
49 Giovannelli I, Bayatti N, Brown A, Wang D, Mickunas M, Camu W, Veyrune JL, Payan C, Garlanda C, Locati M, Juntas-Morales R, Pageot N, Malaspina A, Andreasson U, Suehs C, Saker S, Masseguin C, de Vos J, Zetterberg H, Al-Chalabi A, Leigh PN, Tree T, Bensimon G, Heath PR, Shaw PJ, Kirby J. Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Commun 2021;3:fcab141. [PMID: 34409288 DOI: 10.1093/braincomms/fcab141] [Reference Citation Analysis]
50 Robinson S, Thomas R. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol 2021;12:654701. [PMID: 34335564 DOI: 10.3389/fimmu.2021.654701] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Corfmat M, Willekens C, Vinit J, Bussone G, Fenaux P, Fain O, Klatzmann D, Mekinian A, Comont T; MINHEMON (French network of dysimmune disorders associated to hematological malignancies). Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report. Rheumatology (Oxford) 2021;60:3404-8. [PMID: 33164099 DOI: 10.1093/rheumatology/keaa696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Sharabi A. Updates on Clinical Trials in Systemic Lupus Erythematosus. Curr Rheumatol Rep 2021;23:57. [PMID: 34212269 DOI: 10.1007/s11926-021-01014-w] [Reference Citation Analysis]
53 Estadt SN, Maz MP, Musai J, Kahlenberg JM. Mechanisms of Photosensitivity in Autoimmunity. J Invest Dermatol 2021:S0022-202X(21)01299-9. [PMID: 34167786 DOI: 10.1016/j.jid.2021.05.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Chaichian Y, Wallace DJ. Innovative Trials and New Opportunities in SLE. Rheum Dis Clin North Am 2021;47:481-99. [PMID: 34215375 DOI: 10.1016/j.rdc.2021.04.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Trzupek D, Lee M, Hamey F, Wicker LS, Todd JA, Ferreira RC. Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus. Wellcome Open Res 2021;6:149. [DOI: 10.12688/wellcomeopenres.16883.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Miao M, Xiao X, Tian J, Zhufeng Y, Feng R, Zhang R, Chen J, Zhang X, Huang B, Jin Y, Sun X, He J, Li Z. Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. Arthritis Res Ther 2021;23:167. [PMID: 34116715 DOI: 10.1186/s13075-021-02535-6] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
57 Liang K, He J, Wei Y, Zeng Q, Gong D, Qin J, Ding H, Chen Z, Zhou P, Niu P, Chen Q, Ding C, Lu L, Chen XX, Li Z, Shen N, Yu D, Deng J. Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus. Clin Transl Immunology 2021;10:e1293. [PMID: 34094549 DOI: 10.1002/cti2.1293] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
58 Zhao Q, Dai H, Liu X, Jiang H, Liu W, Feng Z, Zhang N, Gao Y, Dong Z, Zhou X, Du J, Zhang N, Rui H, Yuan L, Liu B. Helper T Cells in Idiopathic Membranous Nephropathy. Front Immunol 2021;12:665629. [PMID: 34093559 DOI: 10.3389/fimmu.2021.665629] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
59 Fan Y, Hao YJ, Zhang ZL. Systemic lupus erythematosus: year in review 2019. Chin Med J (Engl) 2020;133:2189-96. [PMID: 32810049 DOI: 10.1097/CM9.0000000000000983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Dixit N, Fanton C, Langowski JL, Kirksey Y, Kirk P, Chang T, Cetz J, Dixit V, Kim G, Kuo P, Maiti M, Tang Y, VanderVeen LA, Zhang P, Lee M, Ritz J, Kamihara Y, Ji C, Rubas W, Sweeney TD, Doberstein SK, Zalevsky J. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J Transl Autoimmun 2021;4:100103. [PMID: 34041473 DOI: 10.1016/j.jtauto.2021.100103] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
61 Hao H, Nakayamada S, Tanaka Y. Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases. Inflamm Regen 2021;41:14. [PMID: 33934711 DOI: 10.1186/s41232-021-00164-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zhang H, Dai D, Hu Q, Yang F, Xue Y, Li F, Shen N, Zhang M, Huang C. Bach2 attenuates IL-2R signaling to control Treg homeostasis and Tfr development. Cell Rep 2021;35:109096. [PMID: 33979619 DOI: 10.1016/j.celrep.2021.109096] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
63 Narain S, Berman N, Furie R. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Curr Opin Rheumatol 2020;32:609-16. [PMID: 33002950 DOI: 10.1097/BOR.0000000000000754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
64 Maz MP, Michelle Kahlenberg J. Cutaneous and systemic connections in lupus. Curr Opin Rheumatol 2020;32:583-9. [PMID: 32826479 DOI: 10.1097/BOR.0000000000000739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
65 Zhang SX, Wang J, Wang CH, Jia RH, Yan M, Hu FY, Liu GY, Liu XY, Luo J, Gao C, Li XF. Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2021;13:1759720X211011370. [PMID: 33995604 DOI: 10.1177/1759720X211011370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
66 Papillion A, Ballesteros-Tato A. The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses. Front Immunol 2021;12:667342. [PMID: 33986755 DOI: 10.3389/fimmu.2021.667342] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
67 Datta SK. Harnessing Tolerogenic Histone Peptide Epitopes From Nucleosomes for Selective Down-Regulation of Pathogenic Autoimmune Response in Lupus (Past, Present, and Future). Front Immunol 2021;12:629807. [PMID: 33936042 DOI: 10.3389/fimmu.2021.629807] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
68 Wang Y, Zheng J, Islam MS, Yang Y, Hu Y, Chen X. The role of CD4+FoxP3+ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment. Int J Biol Sci 2021;17:1507-20. [PMID: 33907514 DOI: 10.7150/ijbs.59534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
69 Graßhoff H, Comdühr S, Monne LR, Müller A, Lamprecht P, Riemekasten G, Humrich JY. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. Front Immunol 2021;12:648408. [PMID: 33868284 DOI: 10.3389/fimmu.2021.648408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
70 Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev 2021;3:CD007478. [PMID: 33687069 DOI: 10.1002/14651858.CD007478.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Liossis SN, Staveri C. What's New in the Treatment of Systemic Lupus Erythematosus. Front Med (Lausanne) 2021;8:655100. [PMID: 33748165 DOI: 10.3389/fmed.2021.655100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
72 Qian M, Zhang Q, Lu J, Zhang J, Wang Y, Shangguan W, Feng M, Feng J. Long-Acting Human Interleukin 2 Bioconjugate Modified with Fatty Acids by Sortase A. Bioconjug Chem 2021;32:615-25. [PMID: 33656323 DOI: 10.1021/acs.bioconjchem.1c00062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Márquez-García JE, Hernández-Doño S, Ceja-Mendoza ML, Pedraza-Jiménez ML, García-Rivas M, Martínez-Escobar L, Fragoso-Sánchez A, Miranda de la Cruz LF, Granados J. Cytokines and growth factors in a biologic product obtained from patients' urine as immune-modulators to treat autoimmune and allergic diseases. Cytokine 2021;141:155427. [PMID: 33581472 DOI: 10.1016/j.cyto.2021.155427] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Kono M, Nagafuchi Y, Shoda H, Fujio K. The Impact of Obesity and a High-Fat Diet on Clinical and Immunological Features in Systemic Lupus Erythematosus. Nutrients 2021;13:504. [PMID: 33557015 DOI: 10.3390/nu13020504] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
75 Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford) 2020;59:v69-81. [PMID: 33280011 DOI: 10.1093/rheumatology/keaa403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
76 Piga M, Arnaud L. The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? J Clin Med 2021;10:E243. [PMID: 33440874 DOI: 10.3390/jcm10020243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
77 Chen YC, Kuo PY, Chou YC, Chong HE, Hsieh YT, Yang ML, Wu CL, Shiau AL, Wang CR. Up-Regulated Expression of Pro-Apoptotic Long Noncoding RNA lincRNA-p21 with Enhanced Cell Apoptosis in Lupus Nephritis. Int J Mol Sci 2020;22:E301. [PMID: 33396699 DOI: 10.3390/ijms22010301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
78 Giganti G, Atif M, Mohseni Y, Mastronicola D, Grageda N, Povoleri GA, Miyara M, Scottà C. Treg cell therapy: How cell heterogeneity can make the difference. Eur J Immunol 2021;51:39-55. [PMID: 33275279 DOI: 10.1002/eji.201948131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
79 Herrnstadt GR, Steinmetz OM. The role of Treg subtypes in glomerulonephritis. Cell Tissue Res 2021;385:293-304. [PMID: 33315130 DOI: 10.1007/s00441-020-03359-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
80 Kolios AGA, Yoshida N, Tsokos GC. New therapeutic approaches in systemic lupus erythematosus. Curr Opin Rheumatol 2021;33:181-9. [PMID: 33332887 DOI: 10.1097/BOR.0000000000000772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
81 Hao H, Nakayamada S, Yamagata K, Ohkubo N, Iwata S, Inoue Y, Zhang M, Zhang T, Kanda Satoh Y, Shan Y, Otsuka T, Tanaka Y. Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin‐2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. Arthritis Rheumatol 2021;73:132-42. [DOI: 10.1002/art.41457] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
82 Sun H, Zhao Y, Wang K, Zhu L, Dong J, Zhao J, Wang Y, Li H, Sun X, Lu Y. Low dose IL-2 suppress osteoclastogenesis in collagen-induced arthritis via JNK dependent pathway. Immun Inflamm Dis 2020;8:727-35. [PMID: 33098626 DOI: 10.1002/iid3.364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Lv C, Zhang H, Li Z, Zhang H, Zhang Y, Li R, Wei S, Yu D. Low-dose IL-2 therapy compensates for metabolic shifts and reverses anxiety-like behavior in PD-1 deficiency-induced autoimmunity. Cell Mol Immunol 2021;18:1336-8. [PMID: 33067573 DOI: 10.1038/s41423-020-00562-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021;80:14-25. [PMID: 33051219 DOI: 10.1136/annrheumdis-2020-218272] [Cited by in Crossref: 21] [Cited by in F6Publishing: 76] [Article Influence: 10.5] [Reference Citation Analysis]
85 Allen ME, Rus V, Szeto GL. Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. Trends Mol Med 2021;27:152-71. [PMID: 33046407 DOI: 10.1016/j.molmed.2020.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
86 Sandling JK, Pucholt P, Hultin Rosenberg L, Farias FHG, Kozyrev SV, Eloranta ML, Alexsson A, Bianchi M, Padyukov L, Bengtsson C, Jonsson R, Omdal R, Lie BA, Massarenti L, Steffensen R, Jakobsen MA, Lillevang ST, Lerang K, Molberg Ø, Voss A, Troldborg A, Jacobsen S, Syvänen AC, Jönsen A, Gunnarsson I, Svenungsson E, Rantapää-Dahlqvist S, Bengtsson AA, Sjöwall C, Leonard D, Lindblad-Toh K, Rönnblom L; ImmunoArray Development Consortium and DISSECT consortium. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis 2021;80:109-17. [PMID: 33037003 DOI: 10.1136/annrheumdis-2020-218636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
87 Wang H, Feng X, Yan W, Tian D. Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients. Front Immunol 2020;11:575572. [PMID: 33117375 DOI: 10.3389/fimmu.2020.575572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
88 Terry LV, Oo YH. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations. Front Immunol 2020;11:565518. [PMID: 33072105 DOI: 10.3389/fimmu.2020.565518] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
89 Wajda A, Łapczuk-Romańska J, Paradowska-Gorycka A. Epigenetic Regulations of AhR in the Aspect of Immunomodulation. Int J Mol Sci 2020;21:E6404. [PMID: 32899152 DOI: 10.3390/ijms21176404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
90 Khoryati L, Pham MN, Sherve M, Kumari S, Cook K, Pearson J, Bogdani M, Campbell DJ, Gavin MA. An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice. Sci Immunol 2020;5:eaba5264. [PMID: 32817295 DOI: 10.1126/sciimmunol.aba5264] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
91 Cheng L, Zhang H, Wu F, Liu Z, Cheng Y, Wang C. Role of Nrf2 and Its Activators in Cardiocerebral Vascular Disease. Oxid Med Cell Longev 2020;2020:4683943. [PMID: 32831999 DOI: 10.1155/2020/4683943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
92 Yung S, Yap DY, Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. F1000Res 2020;9:F1000 Faculty Rev-905. [PMID: 32789005 DOI: 10.12688/f1000research.22438.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
93 Talotta R, Atzeni F, Laska MJ. Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy. Expert Opin Investig Drugs 2020;29:845-67. [PMID: 32500750 DOI: 10.1080/13543784.2020.1777983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Ghelani A, Bates D, Conner K, Wu MZ, Lu J, Hu YL, Li CM, Chaudhry A, Sohn SJ. Defining the Threshold IL-2 Signal Required for Induction of Selective Treg Cell Responses Using Engineered IL-2 Muteins. Front Immunol 2020;11:1106. [PMID: 32582190 DOI: 10.3389/fimmu.2020.01106] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
95 Bendickova K, Fric J. Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy. J Leukoc Biol 2020;108:427-37. [PMID: 32480431 DOI: 10.1002/JLB.5MIR0420-055R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
96 Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatol Ther 2020;7:433-46. [PMID: 32488652 DOI: 10.1007/s40744-020-00212-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
97 Felten R, Lipsker D, Sibilia J, Chasset F, Arnaud L. The history of lupus throughout the ages. J Am Acad Dermatol 2020:S0190-9622(20)30772-6. [PMID: 32380218 DOI: 10.1016/j.jaad.2020.04.150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
98 Chen AC, Cai X, Li C, Khoryati L, Gavin MA, Miao CH. A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy. Front Immunol 2020;11:638. [PMID: 32411127 DOI: 10.3389/fimmu.2020.00638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Aringer M, Leuchten N, Dörner T. Biologika und „small molecules“ beim systemischen Lupus erythematodes. Z Rheumatol 2020;79:232-40. [DOI: 10.1007/s00393-020-00767-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
100 Wang B, Chen S, Zheng Q, Liu Y, Shi G. Peptide-Based Vaccination Therapy for Rheumatic Diseases. J Immunol Res 2020;2020:8060375. [PMID: 32258176 DOI: 10.1155/2020/8060375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
101 Zhao TX, Newland SA, Mallat Z. 2019 ATVB Plenary Lecture: Interleukin-2 Therapy in Cardiovascular Disease: The Potential to Regulate Innate and Adaptive Immunity. Arterioscler Thromb Vasc Biol 2020;40:853-64. [PMID: 32078364 DOI: 10.1161/ATVBAHA.119.312287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]